| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2021 , Vol 59 , Num 1
Formulation and In vivo Pharmacodynamics studies of Nanostructured Lipid Carriers for Topical Delivery of Bifonazole
1 M.M College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India2 Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra-136119, India
3 Department of Pharmaceutical Sciences, Indira Gandhi University, Meerpur, Rewari, Haryana, India, Pharmaceutics, Rewari, India
4 Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh,, Pharmaceutical Chemistry, Mathura, India
DOI : 10.23893/1307-2080.APS.05902 Viewed : 20957 - Downloaded : 6380 The main objective of the present study was to developed and evaluated the Bifonazole (BFZ) loaded Nanostructured lipid carriers (NLCs) for topical delivery of BFZ. BFZ-NLCs were deve560ted for Particle size, EE, DL and drug release profiles. The invitro release studies show better drug release over 24h as compared to the marketed formulation. Ex-vivo skin permeation and Pharmacodynamic studies indicated that NLCs get effectively reduced the fungal infection. In-vitro antifungal activity study shows that the BFZ-NLCs were more effective in inhibiting the growth of Candida Albicans. Therefore, the study concludes that NLCs showed a continuous release profile and has the prospective for treatment of topical fungal infections. Keywords : Bifonazole, Nanostructured lipid carriers, Topical delivery, Anti-fungal infection, High pressure homogenization